勃起不全(ED)薬の世界市場2019-2023

◆英語タイトル:Global Erectile Dysfunction (ED) Drugs Market 2019-2023
◆商品コード:IRTNTR31071
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年3月27日
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、勃起不全(ED)薬の世界市場について調査・分析し、市場概要、市場環境、勃起不全(ED)薬市場規模、製品別(経口薬、局所薬、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・勃起不全(ED)薬の世界市場概要
・勃起不全(ED)薬の世界市場環境
・勃起不全(ED)薬の世界市場動向
・勃起不全(ED)薬の世界市場規模
・勃起不全(ED)薬の世界市場:業界構造分析
・勃起不全(ED)薬の世界市場:製品別(経口薬、局所薬、その他)
・勃起不全(ED)薬の世界市場:地域別市場規模・分析
・勃起不全(ED)薬の北米市場規模・予測
・勃起不全(ED)薬のヨーロッパ・中東・アフリカ市場規模・予測
・勃起不全(ED)薬のアジア太平洋市場規模・予測
・勃起不全(ED)薬の主要国分析
・勃起不全(ED)薬の世界市場:意思決定フレームワーク
・勃起不全(ED)薬の世界市場:成長要因、課題
・勃起不全(ED)薬の世界市場:競争環境
・勃起不全(ED)薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market’s growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences of ED among elderly as well as young people. As these conditions directly alter the normal physiological levels of hormones, enzymes, and other factors, problems including penile erection have surged considerably in the recent years. These issues will further lead the erectile dysfunction drugs market to register a significant growth in the forthcoming years. Technavio’s analysts have predicted that the erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023.
Market Overview
Rising demand for ED drugs
One of the growth drivers of the global erectile dysfunction (ED) drugs market is the rising demand for ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are expected to propel the growth of the global erectile dysfunction (ED) drugs market during the forecast period.
Side effects of available drugs
One of the challenges in the growth of the global erectile dysfunction (ED) drugs market is the side effects of available drugs. The alterations in the blood flow, which are caused by ED drugs, result in side-effects such as headache, vision changes, and dizziness, which will hinder the growth of the market.
For the detailed list of factors that will drive and challenge the growth of the erectile dysfunction (ED) drugs market during 019-2023, view our report.
Competitive Landscape
The market appears to be moderately concentrated with the presence of a few market players. Many vendors in the market are focusing on expanding research for the development of novel therapies such as stem cells for the treatment of ED. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Oral drugs – Market size and forecast 2018-2023
• Topical drugs – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Eli Lilly and Company
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• VIVUS Inc.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
PART 16: EXPLORE TECHNAVIO


Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for ED
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Oral drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral drugs – Year-over-year growth 2019-2023 (%)
Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018
Exhibit 23: Topical drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Topical drugs – Year-over-year growth 2019-2023 (%)
Exhibit 25: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Others – Year-over-year growth 2019-2023 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Market share by geography 2018-2023 (%)
Exhibit 30: Geographic comparison
Exhibit 31: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America – Year-over-year growth 2019-2023 (%)
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: Bayer AG – Vendor overview
Exhibit 48: Bayer AG – Business segments
Exhibit 49: Bayer AG – Organizational developments
Exhibit 50: Bayer AG – Geographic focus
Exhibit 51: Bayer AG – Segment focus
Exhibit 52: Bayer AG – Key offerings
Exhibit 53: Eli Lilly and Company – Vendor overview
Exhibit 54: Eli Lilly and Company – Business segments
Exhibit 55: Eli Lilly and Company – Organizational developments
Exhibit 56: Eli Lilly and Company – Geographic focus
Exhibit 57: Eli Lilly and Company – Segment focus
Exhibit 58: Eli Lilly and Company – Key offerings
Exhibit 59: Pfizer Inc. – Vendor overview
Exhibit 60: Pfizer Inc. – Business segments
Exhibit 61: Pfizer Inc. – Organizational developments
Exhibit 62: Pfizer Inc. – Geographic focus
Exhibit 63: Pfizer Inc. – Segment focus
Exhibit 64: Pfizer Inc. – Key offerings
Exhibit 65: Teva Pharmaceutical Industries Ltd. – Vendor overview
Exhibit 66: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibit 67: Teva Pharmaceutical Industries Ltd. – Organizational developments
Exhibit 68: Teva Pharmaceutical Industries Ltd. – Geographic focus
Exhibit 69: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibit 70: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibit 71: VIVUS Inc. – Vendor overview
Exhibit 72: VIVUS Inc. – Business segments
Exhibit 73: VIVUS Inc. – Organizational developments
Exhibit 74: VIVUS Inc. – Geographic focus
Exhibit 75: VIVUS Inc. – Key offerings
Exhibit 76: Validation techniques employed for market sizing



【掲載企業】

Bayer AG , Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., VIVUS Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[勃起不全(ED)薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆